Emergence of pristinamycin resistance in India
- PMID: 20177582
- PMCID: PMC2825015
- DOI: 10.4103/0253-7613.48884
Emergence of pristinamycin resistance in India
Abstract
Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resistance. The Minimum inhibitory concentrations (MIC) for pristinamycin in these two cases were 30 mug and 25 mug, respectively. Universal advocacy of pristinamycin for the therapy of MDR GPC infections should be re-evaluated.
Keywords: Dalfopristin/quinupristin; pristinamycin resistance; staphylococcus.
References
-
- Chamber HF. Antimicrobial agents: Protein synthesis inhibitors and miscellaneous antibacterial agents. In: Burton LL, Lazo JS, Parker KL, editors. Goodman and Gillman.s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006. pp. 1173–202.
-
- El Solh N, Allignet J. Staphylococcal resistance to streptogramins and related antibiotics. Drug Resist Updates. 1998;1:169–75. - PubMed
-
- Weisblum B. Resistance to the macrolide –lincosamide –streptogramin antibiotics. In: Fischetti VA, editor. Gram-positive pathogens. Washington, DC: ASM Press; 2000. pp. 694–710.